“FDA clearance comes at the perfect time, with guidelines being adopted clinically for cardiac CT and with positive reimbursement driving procedure growth," says Jean-Luc Procaccini, CEO, molecular imaging and CT.
Members of the specialty should begin their next job with an exit strategy in mind or risk losing a hefty sum in the process, according to a new opinion piece.
Satoshi Minoshima, MD, PhD, first took on the title in November 2014 and will remain in a clinical role while IR specialist Chuck Ray, MD, PhD, takes over as interim chair.
Researchers with Northwestern University in Chicago detailed their novel system in an analysis published by the Journal of the American College of Radiology.
Both the complexity and volume of deals has soared in recent years, the agency noted, prompting the need to review premerger forms for the first time in years.
The findings were reached using an analytic hierarchy process, which can help physicians review options with patients who have never experienced either exam.
“FDA clearance comes at the perfect time, with guidelines being adopted clinically for cardiac CT and with positive reimbursement driving procedure growth," says Jean-Luc Procaccini, CEO, molecular imaging and CT.
Jaime Warren, EdD, FACC, vice president of care transformation at MedAxiom, an ACC company, explains what is needed to address staffing shortages created by a 94% increase in cardiac CT volumes over the past 5 years.
